Innovative vaccine approaches—a Keystone Symposia report

Creators: Cable, Jennifer; Rappuoli, Rino¹; Klemm, Elizabeth J.²; Kang, Gagandeep³; Mutreja, Ankur⁴; Wright, Gavin J.^{5, 6}; Pizza, Mariagrazia¹; Ajay Castro, Sowmya⁷; Hoffmann, Joseph P.⁸; Alter, Galit^{9, 10}; Carfi, Andrea¹¹; Pollard, Andrew J.¹²; Krammer, Florian¹³; Gupta, Ravindra K.^{4, 14}; Wagner, Caroline E.¹⁵; Machado, Viviane¹⁶; Modjarrad, Kayvon¹⁷; Corey, Lawrence^{18, 19}; Gilbert, Peter B.¹⁹; Dougan, Gordon⁴; Lurie, Nicole^{20, 9}; Bjorkman, Pamela J.²¹; Chiu, Christopher²²; Nemes, Elisa²³; Gordon, Stephen B.²⁴; Steer, Andrew C.^{25, 26, 27}; Rudel, Thomas²⁸; Blish, Catherine A.^{29, 30}; Sandberg, John Tyler³¹; Brennan, Kiva³²; Klugman, Keith P.³³; Stuart, Lynda M.^{34, 35}; Madhi, Shabir A.³⁶; Karp, Christopher L.³⁵

1. GlaxoSmithKline (Italy)
2. Wellcome Trust
3. Christian Medical College & Hospital
4. University of Cambridge
5. Wellcome Sanger Institute
6. University of York
7. University of Dundee
8. Tulane University
9. Harvard University
10. Massachusetts General Hospital
11. Moderna Therapeutics (United States)
12. University of Oxford
13. Icahn School of Medicine at Mount Sinai
14. Africa Health Research Institute
15. McGill University
16. Oswaldo Cruz Foundation
17. Walter Reed Army Institute of Research
18. University of Washington
19. Fred Hutchinson Cancer Research Center
20. Coalition for Epidemic Preparedness Innovations
21. California Institute of Technology
22. Imperial College London
23. South African Tuberculosis Vaccine Initiative
24. Malawi-Liverpool-Wellcome Trust Clinical Research Programme
25. Murdoch Children's Research Institute
26. University of Melbourne
27. Royal Children's Hospital
28. University of Würzburg
29. Stanford University
30. CZ Biohub
31. Karolinska Institute
32. Trinity College Dublin
33. Emory University
34. Virginia Mason Medical Center
35. Bill & Melinda Gates Foundation
36. University of the Witwatersrand

Style

An error occurred while generating the citation.

Abstract

The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well as several novel changes to the vaccine discovery and development processes that partnered industry and governments. And while vaccines offer the potential to drastically improve global health, low-and-middle-income countries around the world often experience reduced access to vaccines and reduced vaccine efficacy. Addressing these issues will require novel vaccine approaches and platforms, deeper insight how vaccines mediate protection, and innovative trial designs and models. On June 28–30, 2021, experts in vaccine research, development, manufacturing, and deployment met virtually for the Keystone eSymposium "Innovative Vaccine Approaches" to discuss advances in vaccine research and development.

Additional Information

© 2022 New York Academy of Sciences. Issue Online: 16 May 2022; Version of Record online: 14 January 2022; Manuscript accepted: 03 December 2021; Manuscript received: 03 December 2021. The authors declare no competing interests.

Attached Files

Published - Annals_NY_Academy_of_Science_-_2022_-_Cable_-_Innovative_vaccine_approaches_a_Keystone_Symposia_report.pdf

Files

Annals_NY_Academy_of_Science_-_2022_-_Cable_-_Innovative_vaccine_approaches_a_Keystone_Symposia_report.pdf

Files (1.6 MB)

Name	Size	Download all
Annals_NY_Academy_of_Science_-_2022_-_Cable_-_Innovative_vaccine_approaches_a_Keystone_Symposia_report.pdf md5:a220847b0d195168685dd740a23e952d	1.6 MB	Preview Download

Additional details

	All versions	This version
Views	45	45
Downloads	16	16
Data volume	25.0 MB	25.0 MB